tetano
Editor, Senior Moderator
Front Immunol
. 2022 Jul 22;13:911164.
doi: 10.3389/fimmu.2022.911164. eCollection 2022.
Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate
Shan Mei[SUP] 1 [/SUP], Zhangling Fan[SUP] 1 [/SUP], Xiaoman Liu[SUP] 1 [/SUP], Fei Zhao[SUP] 1 [/SUP], Yu Huang[SUP] 1 [/SUP], Liang Wei[SUP] 1 [/SUP], Yamei Hu[SUP] 1 [/SUP], Yu Xie[SUP] 1 [/SUP], Liming Wang[SUP] 2 [/SUP], Bin Ai[SUP] 2 [/SUP], Chen Liang[SUP] 3 [/SUP], Fengwen Xu[SUP] 1 [/SUP], Fei Guo[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.
Keywords: COVID-19; SARS-CoV-2; spike protein; vaccine; vaccinia virus.
. 2022 Jul 22;13:911164.
doi: 10.3389/fimmu.2022.911164. eCollection 2022.
Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate
Shan Mei[SUP] 1 [/SUP], Zhangling Fan[SUP] 1 [/SUP], Xiaoman Liu[SUP] 1 [/SUP], Fei Zhao[SUP] 1 [/SUP], Yu Huang[SUP] 1 [/SUP], Liang Wei[SUP] 1 [/SUP], Yamei Hu[SUP] 1 [/SUP], Yu Xie[SUP] 1 [/SUP], Liming Wang[SUP] 2 [/SUP], Bin Ai[SUP] 2 [/SUP], Chen Liang[SUP] 3 [/SUP], Fengwen Xu[SUP] 1 [/SUP], Fei Guo[SUP] 1 [/SUP]
Affiliations
- PMID: 35935962
- PMCID: PMC9353262
- DOI: 10.3389/fimmu.2022.911164
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.
Keywords: COVID-19; SARS-CoV-2; spike protein; vaccine; vaccinia virus.